THERAPY DOSSIER · th-b41e8da726b7

Flightless I small interfering RNA loaded into chitosan-coated thermally hydrocarbonised porous silicon nanoparticles

Other

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Wound
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 33465882 ↗2016Reported benefit

Delivery of Flightless I siRNA from Porous Silicon Nanoparticles Improves Wound Healing in Mice.

MouseWoundIntradermal injectionLoading of the order of 50 micrograms of siRNA per mg of po…

Model: Acute excisional skin wounds

Intradermal delivery of Flightless I siRNA loaded porous silicon nanoparticles significantly improved healing of acute excisional wounds compared with controls from day 5 onwards, with reduced Flightless I expression and increased keratinocyte migration and proliferation.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…